Overview

Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Status:
Not yet recruiting
Trial end date:
2025-10-25
Target enrollment:
Participant gender:
Summary
This is a phase I/II, open-Label, dose-Escalation and dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 (an Anti-CCR8 mAb) as a Single Agent or in combination with Toripalimab in Advanced Solid Tumours.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
LaNova Medicines Limited